Valuation check: BXRX's profit margin is -2201.54%, below the Healthcare sector average of 9.48%.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2023
Trailing 12 months ending Sep 2023
As of the most recent data (September 2023), BXRX shows a profit margin of -2201.54%. That compares with -1656.84% in the prior-year period — down 32.9% year over year. That is below the Healthcare sector average of 9.48%. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, BXRX's profit margin is now -2201.54% (was -1656.84%) — a 32.9% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Baudax Bio is outperforming or lagging.
The Healthcare sector average profit margin is about 9.48%. Baudax Bio is at -2201.54%, which is lower that average. That is roughly 23320.6% below the sector mean. Use the comparison chart on this page to see how BXRX stacks up against individual peers as well.
That compares with -1656.84% in the prior-year period — down 32.9% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Baudax Bio with peers to see if the move is company-specific or sector-wide.
Besides this profit margin page, Stockcircle has Baudax Bio's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently -2201.54%) with ownership activity and broader fundamentals.